Beirne Wealth Consulting Services, LLC Biogen Inc. Transaction History

Beirne Wealth Consulting Services, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 14, 2020	SELL	$220.06 - $304.07 $543,768 - $751,356	-2,471 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$217.44 - $243.88 $6,088 - $6,828	-28 Reduced 1.12%	2,471 $575,000
Q2 2019 Jul 25, 2019	SELL	$219.29 - $241.72 $118,635 - $130,770	-541 Reduced 17.8%	2,499 $584,000
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $399,179 - $624,364	1,842 Added 153.76%	3,040 $719,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $333,643 - $422,594	1,198 New	1,198 $361,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Beirne Wealth Consulting Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Beirne Wealth Consulting Services, LLC with notifications on news.